ArticleBMC ophthalmology2025
Iron-associated central macular ganglion cell complex thinning and choroidal vascularity index elevation in transfusion-dependent β-thalassemia: potential OCT/OCTA biomarkers.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to evaluate alterations in macular microstructure and blood flow density in patients with transfusion-dependent β-thalassemia (TDT) using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA), and to explore their associations with markers of iron metabolism.
methodsA cross-sectional study was conducted involving 31 TDT patients (61 eyes) and 31 age- and sex-matched healthy controls (61 eyes) at the Affiliated Hospital of Guangdong Medical University from October 2022 to December 2023. Data collected included basic information, medical history, best-corrected visual acuity, ocular biometry, fundus photography, and OCT/OCTA imaging. Parameters assessed comprised the thickness and blood flow density of individual macular layers, as well as choroidal stromal area, choroidal luminal area, and choroidal vascular index (CVI). Pearson correlation analysis was employed to examine relationships among macular parameters, serum ferritin (SF) levels, duration of iron chelation therapy (ICT), and other variables.
resultsCompared to healthy controls, TDT patients exhibited significant thinning of the central macular area ganglion cell layer, retinal nerve fiber layer, and ganglion cell complex (mGCC), accompanied by increased blood flow density in the deep vascular complex, nerve fiber layer vascular plexus, and deep capillary plexus (all P < 0.05). The choroidal stromal area was reduced (P = 0.037), whereas CVI was elevated (P = 0.034). Pearson correlation analysis revealed a positive correlation between central mGCC thickness and the duration of ICT (r = 0.280, P < 0.05),and a significant positive correlation between CVI with SF levels (r = 0.426, P < 0.01). Stepwise linear regression analysis identified the duration of ICT (β = 0.306, P = 0.011) as a significant independent factor influencing central mGCC thickness. Similarly, SF levels significantly influenced CVI (β = 0.469, P < 0.001). Additionally, 62.30% of TDT patients' eyes presented with tilted optic discs, 34.43% showed tessellated fundus, and 6.56% had pseudoxanthoma elasticum.
conclusionsTDT patients exhibit both macular neuroretinal thinning and increased microvascular blood flow density. CVI and central mGCC thickness may serve as potential biomarkers for monitoring iron-related ocular pathology and therapeutic efficacy. Future longitudinal studies are warranted to validate their predictive value and establish causality. Regular ocular screening is warranted in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.